Senior professionals in life sciences business development, finance, and forecasting are welcome to register for this event.
Share:
Register your interest today. Speaker confirmation and agenda to follow.
Daniel Chancellor, Director of Thought Leadership at Norstella, will open the session with pipeline-to-productivity and state of the industry keynote, followed by a fireside chat with a leading figure from the pharma industry.
Daniel Chancellor
VP, Thought Leadership, Norstella
Dr Tony Wood
Chief Scientific Officer, GSK
Helen Ho, Ph.D.
Chief Business and Strategy Officer, Parabilis
The Clermont Charing Cross sits at the heart of London Life Sciences Week activity, ideally placed within a short walk of the week’s key conference and networking venues along the Strand and Aldwych.
An invitation-only format designed to bring together the right people for candid, peer-level conversation.
Hear directly from the team behind the Pipeline to Patient Productivity Index on what the data tells us about the year ahead.
A frank, off-the-record discussion on the commercial pressures shaping strategy in 2026 and beyond.
| Time | Session | Speaker |
|---|---|---|
| 8.00 am | Registration + Breakfast | |
| 9.00 am | Welcome Keynote | Lucie Ellis-Taitt, Editor-in-Chief, Health and Medtech |
| 9.10 am |
Pharma’s Productivity Crunch
This session shares the key findings from our inaugural Pipeline-to-Patient Productivity Index, which scores how pharma companies perform in developing new medicines. R&D costs have risen over the last five years, and commercial returns are growing unevenly. Many companies now face a productivity crunch and need to rethink their drug development strategies and pipeline investments. |
Daniel Chancellor, VP, Thought Leadership, Norstella |
| 9.30 am |
Fireside Chat in partnership with Scrip
Tony will discuss GSK’s R&D strategy, recent clinical trial successes and drug approvals, plus its approach to partnerships and cutting-edge tech to re-design innovation for tomorrow. |
Tony Wood, Chief Scientific Officer, GSK
Melanie Senior, Specialist Writer Life Sciences, Evaluate |
| 10:00 am |
Fireside Chat in Partnership with Scrip
Parabilis achieved a record-breaking IPO in June to support its novel peptide-based platform, which targets previously undruggable intracellular targets. Helen will discuss the company’s pipeline and strategy plus wider sector issues, including the deal and financing climate and R&D productivity. |
Helen Ho, Ph.D Chief Business and Strategy Officer, Parabilis Andrew McConaghie, Senior Writer, Scrip |
| 10:30 am | Close |
Scrip provides in-depth analysis of the global biopharma industry, offering news that goes beyond the headlines. Our journalists will be in attendance at the event – stop and say hello or connect with them ahead of the day:
